- Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year.
- Shares recently set a new 3-year high.
- PSNL stock maintains a 100% “Buy” technical opinion from Barchart.
- Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest.
Today’s Featured Stock
Valued at $1.8 billion, Personalis (PSNL) is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient’s cancer and immune response.
What I’m Watching
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. PSNL checks those boxes. The Trend Seeker issued a new “Buy” signal on Aug. 10. Since then, the stock has gained 17.39%.

Barchart’s Technical Indicators for Personalis
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
Personalis scored a 3-year high of $18.89 on Aug. 21.
- Personalis has a Weighted Alpha of 152.59.
- PSNL has a 100% “Buy” opinion from Barchart.
- The stock has gained 248.16% over the past 52 weeks.
- Personalis has its Trend Seeker “Buy” signal intact.
- The stock recently traded at $17.02 with a 50-day moving average of $13.65.
- PSNL had 12 new highs and gained 44.23% in the last month.
- 60-month beta of 2.27.
- Relative Strength Index (RSI) is at 64.94.
- There’s a technical support level around $16.87.
Don’t Forget the Fundamentals
- $1.8 billion market capitalization.
- Revenue is projected to grow 18.4% this year and another 33.63% next year.
- Earnings are estimated to decrease by 20.05% this year but increase again by 13.89% next year.
Analyst and Investor Sentiment on Personalis
- The Wall Street analysts followed by Barchart give the stock 2 “Strong Buy,” 3 “Hold,” and 1 “Strong Sell” opinions with price targets between $10.00 and $16.25.
- Value Line does not rate the stock but notes it had a 58.41% total return last year.
- Morningstar thinks the stock is 23% undervalued with a fair value of $22.18.
- CFRA’s MarketScope rates the stock as “Sell.”
- 5,950 investors are following the stock on Seeking Alpha, which rates it a “Hold.”
- TipRanks’ analysts’ consensus price target is $15.95 for a 7.54% loss.
- Short interest is 8.32% of the float with 1.64 days to cover the float.
The Bottom Line on Personalis
Although the stock has shown impressive momentum, the operations of the company have still not produced a profit. Personalis is highly speculative here.
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculate should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.